TransMedics Group, Inc. (TMDX) - Stock Analysis
Last updated: Mar 9, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
TransMedics exhibits strong fundamentals with 32% Q3 revenue growth, expanding profitability, international launch imminent, and key clinical trials underway. Though near-term technical momentum is bearish, medium-term growth prospects and pipeline catalysts make it a watch-for-entry hot idea.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Strong cash reserve ⢠High gross margins ⢠Elevated leverage TMDX shows exceptional liquidity and cash-backed net debt neutrality with strong margins and FCF, but faces elevated operating costs, above-average leverage and accounting/quarterly margin volatility while trading at rich multiples.
Price Behavior
Key Price Behavior Insights: ⢠Flat month close ⢠Sharp reversal ⢠Elevated volatility Support Level: $129.60 Resistance Level: $141â$148 Over the last month TMDX is essentially flat (129.60â129.61) after a rally to $148 and a rapid reversal, leaving support near $129.60, resistance at $141â$148, and elevated short-term downside risk from the ~14% high-to-low swing.
Sentiment & News
Key News Insights: ⢠Strong EPS/revenue ⢠IDE approval ⢠Upgraded guidance TransMedics beat Q4 expectations with 32% revenue growth and 200% EPS surge, raised 2026 growth guidance (~high single- to mid-double-digits), secured IDE approval for nextâgen OCS ENHANCE Heart, and saw positive market/analyst reaction.
AI Summary
TransMedics has shifted from an R&Dâoptional medâdevice story into a cashâgenerative, marginâexpanding commercial operator where fleet utilization and timely heart/lung trial enrollmentârather than distant product approvalsâwill determine upside, so investors should focus on quarterly fleet utilization metrics, FCF consistency, and ENHANCE/DENOVO enrollment milestones as the primary catalysts. Failure to ramp doubleâshift NOP utilization or to hit IDE/trial timelines would materially compress margins and justify valuation downside.
Description
TransMedics Group is a commercial-stage medical technology company that develops and commercializes portable systems for perfusion, preservation and monitoring of donor organs to support transplantation in the U.S. and abroad. Its Organ Care System recreates near-physiologic conditions ex vivo and includes device variants for lungs, hearts and livers. The company was founded in 1998 and is headquartered in Andover, Massachusetts.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Dec 25 | Jan 1 | TMDX | TransMedics Group, Inc. | TransMedics exhibits strong fundamentals with 32% Q3 revenue growth, expanding profitability, international launch imminent, and key clinical trials underway. Though near-term technical momentum is bearish, medium-term growth prospects and pipeline catalysts make it a watch-for-entry hot idea. | Closed | -4.2% |
| Sep 8 | Sep 15 | TMDX | TransMedics Group, Inc. | TransMedics delivered robust Q2 revenue (+38% YoY), raised 2025 guidance, received an FDA conditional approval for a key trial (Aug 2025), and shows strong technical momentum with clear near-term catalysts, although ongoing litigation and valuation levels advise cautious position sizing. | Closed | +8.3% |